
BioLife Solutions (BLFS) Stock Forecast & Price Target
BioLife Solutions (BLFS) Analyst Ratings
Bulls say
BioLife Solutions Inc. reported significant growth in its Cell Processing revenue, achieving $25.3 million, which reflects a 33% year-over-year increase, contributing to a total revenue of $28.1 million for 3Q25 and showcasing 31% year-over-year growth on a proforma basis. The company's ability to report net income of $0.6 million, compared to an anticipated loss, indicates improved financial performance and operational efficiency. Furthermore, management's expectation of maintaining a gross margin in the low-60% range and reducing net loss, alongside a strong cash position, supports a favorable outlook for future growth and sustainability in the cell and gene therapy market.
Bears say
BioLife Solutions faces several fundamental risks that contribute to a negative outlook on its stock, including the potential for lower-than-anticipated growth of its products and services, which is evident from the removal of approximately $8 million in revenue guidance for FY2025. The company is also at risk of not securing additional customers, and it may experience fluctuations in sales in emerging markets due to varying foreign exchange rates. Furthermore, there is a potential dilution risk that could adversely affect existing shareholders, compounding concerns over the company's revenue generation and overall growth prospects.
This aggregate rating is based on analysts' research of BioLife Solutions and is not a guaranteed prediction by Public.com or investment advice.
BioLife Solutions (BLFS) Analyst Forecast & Price Prediction
Start investing in BioLife Solutions (BLFS)
Order type
Buy in
Order amount
Est. shares
0 shares